56 related articles for article (PubMed ID: 22768586)
1. [Glinides].
Mita T; Watada H
Nihon Rinsho; 2012 May; 70 Suppl 3():608-13. PubMed ID: 22768586
[No Abstract] [Full Text] [Related]
2. [Sulfonylureas and glinides].
Kudo K; Hirose T
Nihon Rinsho; 2011 Jan; 69 Suppl 1():645-53. PubMed ID: 21766676
[No Abstract] [Full Text] [Related]
3. [Sulfonylureas and glinides].
Hirose T
Nihon Rinsho; 2006 Dec; 64 Suppl 9():646-53. PubMed ID: 17458297
[No Abstract] [Full Text] [Related]
4. [New glucose regulator. More comfort for the type 2 diabetic patient].
MMW Fortschr Med; 2001 Feb; 143(6):57. PubMed ID: 11247371
[No Abstract] [Full Text] [Related]
5. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
6. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
7. Senaglinide. A 4166, AY 4166, Fastic, SDZ DJN 608, Starlix, Starsis, YM 026, Nateglinide.
Drugs R D; 1999 Aug; 2(2):123-6. PubMed ID: 10820657
[No Abstract] [Full Text] [Related]
8. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
9. Glycaemic control in type 2 diabetes.
Campbell A
Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416
[No Abstract] [Full Text] [Related]
10. FDA approves nateglinide for treatment of type 2 diabetes.
Lieder TR
Am J Health Syst Pharm; 2001 Feb; 58(4):285, 288. PubMed ID: 11225164
[No Abstract] [Full Text] [Related]
11. [Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
Nakashima E
Nihon Rinsho; 2015 Mar; 73(3):416-23. PubMed ID: 25812367
[TBL] [Abstract][Full Text] [Related]
12. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Sevinc A
Arch Intern Med; 2003 Jul; 163(14):1741. PubMed ID: 12885691
[No Abstract] [Full Text] [Related]
13. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide for type 2 diabetes.
Med Lett Drugs Ther; 2001 Apr; 43(1101):29-30. PubMed ID: 11283474
[No Abstract] [Full Text] [Related]
16. [COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].
MMW Fortschr Med; 2011 Mar; 153(11):17. PubMed ID: 22165624
[No Abstract] [Full Text] [Related]
17. [Non-SU, insulin secretagogues].
Kikuchi M
Nihon Rinsho; 1999 Mar; 57(3):702-8. PubMed ID: 10199157
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
20. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
